readthroughSign in
CompanyREPLNasdaqWoburn, MA

Replimune, Inc.

Replimune develops oncolytic immunotherapies based on a modified HSV-1 platform designed to induce immunogenic cell death and systemic anti-tumor immune responses.

SCHEDULE 13G/ANov 16Latest SEC filing
Oct 28Latest story